List of Excipients in Branded Drug OPSYNVI

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actelion Pharmaceuticals US Inc	OPSYNVI	macitentan and tadalafil	66215-814	CELLULOSE, MICROCRYSTALLINE	2031-03-22
Actelion Pharmaceuticals US Inc	OPSYNVI	macitentan and tadalafil	66215-814	HYDROXYPROPYL CELLULOSE	2031-03-22
Actelion Pharmaceuticals US Inc	OPSYNVI	macitentan and tadalafil	66215-814	HYPROMELLOSE	2031-03-22
Actelion Pharmaceuticals US Inc	OPSYNVI	macitentan and tadalafil	66215-814	LACTOSE MONOHYDRATE	2031-03-22
Actelion Pharmaceuticals US Inc	OPSYNVI	macitentan and tadalafil	66215-814	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE	2031-03-22
Actelion Pharmaceuticals US Inc	OPSYNVI	macitentan and tadalafil	66215-814	MAGNESIUM STEARATE	2031-03-22

Opsynvi Excipient Strategy and Commercial Opportunities: Formulation, Patent Risk, and Generic Entry Analysis

Last updated: November 6, 2026

Opsynvi is a fixed-dose combination of macitentan and tadalafil approved by the FDA for adults with pulmonary arterial hypertension. Its commercial value comes from combining two established PAH mechanisms in one tablet, reducing pill burden and supporting earlier use of combination therapy. The main excipient opportunity is not a novel inactive ingredient. It is the development of a robust, differentiated solid oral platform that manages the poor aqueous solubility, dose imbalance, dissolution requirements, and long-term stability of both active ingredients.

Opsynvi contains macitentan 10 mg and tadalafil in 20 mg or 40 mg strengths. The product is marketed by Janssen Pharmaceuticals, a Johnson & Johnson company, through the Actelion PAH franchise. FDA approval was granted in March 2024.[1]

What is Opsynvi and how does its formulation create excipient opportunities?

Opsynvi is an immediate-release, film-coated tablet containing:

Product	Macitentan	Tadalafil	Dosage form
Opsynvi 10 mg/20 mg	10 mg	20 mg	Film-coated tablet
Opsynvi 10 mg/40 mg	10 mg	40 mg	Film-coated tablet

Macitentan is an endothelin receptor antagonist. Tadalafil is a phosphodiesterase-5 inhibitor. Both compounds have limited aqueous solubility, but their formulation risks are different.

Macitentan is used at a low dose and has relatively high potency. Tadalafil is used at a substantially higher dose and can drive tablet mass, dissolution performance, and content-uniformity requirements. A formulation must therefore accommodate a 1:2 or 1:4 macitentan-to-tadalafil dose ratio without compromising blend uniformity or release performance.

The U.S. prescribing information identifies conventional tablet excipients, including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, colloidal silicon dioxide, magnesium stearate, and film-coating components.[2] This profile indicates a conventional immediate-release formulation rather than a publicly disclosed lipid-based, depot, osmotic, or long-acting delivery system.

What technical problems must an Opsynvi generic solve?

A competing manufacturer would need to demonstrate:

• Acceptable dissolution for both active ingredients across relevant pH conditions.
• Consistent macitentan content in a tablet containing a larger tadalafil load.
• Chemical and physical stability during storage.
• Low sensitivity to lubricant overmixing.
• Adequate tablet hardness without delayed disintegration.
• Reproducible performance at both 10/20 mg and 10/40 mg strengths.
• Bioequivalence to the reference product under FDA requirements.
• Control of polymorphism, particle-size distribution, and agglomeration for tadalafil and macitentan.

The commercial formulation challenge is the interaction between the two active ingredients, not the complexity of the inactive-ingredient list alone. A generic can use different excipients if it achieves the required pharmaceutical equivalence and bioequivalence. That creates room for excipient suppliers and formulation developers to compete around process capability rather than exact ingredient matching.

Which excipient platforms are most relevant to Opsynvi?

Direct-compression platforms

Microcrystalline cellulose, lactose, colloidal silicon dioxide, and a superdisintegrant can support direct compression. This route has a low manufacturing cost and a short process train. Its main risk is poor blend uniformity caused by the low dose of macitentan relative to the higher tadalafil load.

A direct-compression formulation is most commercially attractive when both active ingredients have suitable flow and compressibility. Particle engineering or ordered mixing may be needed to prevent segregation.

Wet-granulation platforms

Wet granulation can improve flow, content uniformity, and compactibility. Povidone or another binder can help produce a stable granule structure. The process introduces risks for moisture-sensitive materials, residual moisture, and possible changes in dissolution.

A split-granulation approach could be valuable. Macitentan and tadalafil could be granulated separately with different excipient systems before final blending. This may improve dose uniformity and allow independent control of each active ingredient’s dissolution.

Dry-granulation platforms

Roller compaction can reduce water exposure and support continuous or high-throughput manufacturing. It may be useful if either active ingredient shows hydrolytic sensitivity or if wet processing changes particle morphology.

The principal risks are overcompaction, slower disintegration, and ribbon-density variation. These issues can be managed through granule porosity, lubricant concentration, and disintegrant placement.

Solubility-enhancing excipients

Potential enabling technologies include:

• Surfactants such as sodium lauryl sulfate or poloxamers.
• Copovidone or povidone-based amorphous dispersion systems.
• Crospovidone and other high-capacity disintegrants.
• Precipitation inhibitors.
• Co-processed excipients that improve wetting and compaction.
• Particle-size reduction and surface-area engineering.
• pH-modifying excipients where compatible with stability and dissolution.

A solid dispersion may improve tadalafil dissolution, but it can increase manufacturing complexity and physical-stability risk. Surfactants may improve wetting but can affect tablet mechanical properties, gastrointestinal tolerability, and comparative dissolution. A formulation that uses the minimum enabling excipient load may have the strongest cost and regulatory profile.

Film-coating opportunities

Film coating can provide color differentiation between strengths, improve swallowability, and protect the tablet from light and environmental exposure. It is unlikely to create a major stand-alone commercial barrier unless the coating controls moisture ingress, protects a sensitive solid-state form, or supports a modified-release or abuse-deterrent design.

The strongest coating opportunity is operational: using a standard aqueous film-coating system with reliable color matching, low defect rates, and short coating cycles.

What patents protect Opsynvi and when does exclusivity expire?

Opsynvi exclusivity has several possible components:

Exclusivity layer	Relevance to Opsynvi
New-drug exclusivity	Covers the FDA-approved combination under the applicable NDA framework
Composition patents	May cover the macitentan-tadalafil combination or dosage ratios
Formulation patents	May cover excipient systems, dissolution profiles, solid-state forms, or manufacturing processes
Method-of-use patents	May cover treatment of PAH with the fixed-dose combination
Active-ingredient patents	Older macitentan and tadalafil patents may have separate histories
Pediatric exclusivity	Applies only if granted for qualifying pediatric studies
Regulatory exclusivity for the combination	Can restrict certain abbreviated applications for the approved product

The FDA approved Opsynvi under NDA 218368 in March 2024.[1] The public FDA label identifies the product and its approved strengths but does not, by itself, establish the full scope of the Orange Book-listed patent estate.

The commercial question is whether a later applicant can file an ANDA with a Paragraph IV certification before the listed patents expire. A generic applicant can challenge patents covering the combination, formulation, method of use, or approved labeling. The practical launch date depends on the patents listed in the Orange Book, the applicant’s certification strategy, litigation, settlement terms, and any applicable 30-month stay.

How strong is the patent estate for Opsynvi?

The formulation estate is likely stronger if it claims a narrow combination architecture rather than only the use of macitentan and tadalafil together. Claims that may create meaningful barriers include:

• Specific macitentan-to-tadalafil ratios.
• Defined dissolution thresholds for both actives.
• Co-location or segregation of the two active ingredients within a tablet.
• Defined particle-size ranges.
• Amorphous or crystalline forms.
• Stability limits after accelerated storage.
• Specific manufacturing steps that produce a bioequivalent product.
• Use of a particular excipient class to solve a demonstrated technical problem.

Broad claims directed only to combining two known PAH agents may face greater validity and obviousness pressure. Narrow claims linked to improved dissolution, stability, or clinical performance may be more defensible, but their infringement scope may be easier for a generic manufacturer to design around.

The Orange Book should be reviewed for live listings and patent expiration dates before any freedom-to-operate conclusion. FDA’s Orange Book identifies approved drug products, listed patents, and exclusivity information.[3]

What is the Orange Book and Paragraph IV risk for Opsynvi?

Opsynvi is a small-molecule product, so generic competition will proceed through the ANDA pathway rather than the biosimilar pathway. Biosimilar risk does not apply to macitentan or tadalafil because neither is a biologic.

A generic applicant may pursue:

1. Paragraph III certification, accepting launch after patent expiry.
2. Paragraph IV certification, alleging that a listed patent is invalid, unenforceable, or not infringed.
3. A section viii statement that omits a patented method of use from the proposed label.
4. A formulation design that avoids specific composition or process claims.

The most commercially important challenge would likely target formulation or combination patents rather than the active ingredients themselves. Tadalafil and macitentan have separate commercial histories, and the relevant patent positions for each compound may not align with the fixed-dose combination.

A Paragraph IV filing can trigger patent litigation and a potential 30-month stay of final ANDA approval under the Hatch-Waxman framework. Settlement agreements can establish a future generic launch date, an authorized-generic arrangement, or a license with restrictions. No settlement terms should be assumed without verified court or regulatory filings.

What commercial opportunities exist for excipient suppliers and formulation developers?

Generic Opsynvi supply

The most direct opportunity is supplying a formulation platform to an ANDA sponsor. A successful platform would reduce development time across both strengths and provide:

• A scalable blending or granulation process.
• Strong content-uniformity control.
• Robust dissolution across pH conditions.
• Low tablet-mass growth.
• Stable performance under ICH conditions.
• A credible design-around position against listed formulation claims.

Excipient suppliers with co-processed direct-compression systems, high-functionality disintegrants, and solubility-enhancing polymers are positioned to participate in this market.

Second-generation fixed-dose combinations

The approved product uses an immediate-release tablet. Future opportunities could include:

• A smaller tablet through higher drug loading.
• A once-daily formulation with improved swallowability.
• A dispersible or orally disintegrating presentation for patients with swallowing difficulty.
• A sprinkle formulation for selected patient populations, if clinically and regulatorily justified.
• A packaging system that improves adherence and moisture protection.
• A formulation optimized for reduced food-effect variability.

Any alternate dosage form would require clinical and regulatory development. It would also need a commercial rationale because Opsynvi already provides once-daily fixed-dose combination therapy.

Hospital and specialty-pharmacy channels

PAH products are generally distributed through specialty pharmacies and specialist treatment centers. A formulation with lower tablet burden, simpler storage, or improved administration could support payer and specialty-pharmacy differentiation.

The strongest value proposition is likely adherence. Patients with PAH often receive combination therapy and complex monitoring. Reducing separate prescriptions can improve refill coordination and reduce opportunities for missed doses.

Regional and emerging-market products

A lower-cost fixed-dose combination could have commercial potential outside the United States, subject to local regulatory requirements and patent status. Excipient selection matters in markets with:

• High temperature and humidity.
• Limited cold-chain infrastructure.
• Variable excipient availability.
• More constrained manufacturing capabilities.
• Different pharmacopoeial requirements.

A formulation based on globally available lactose, microcrystalline cellulose, crospovidone or croscarmellose sodium, povidone, colloidal silica, and magnesium stearate may have a supply-chain advantage over a platform dependent on specialized polymers.

How does Opsynvi compare with competing PAH products?

Product	Active ingredient or combination	Formulation position	Competitive relevance
Opsynvi	Macitentan/tadalafil	Fixed-dose oral tablet	Reduces pill burden for combination therapy
Opsumit	Macitentan	Oral tablet	Same endothelin-pathway franchise without tadalafil
Adcirca	Tadalafil	Oral tablet	Tadalafil monotherapy in PAH
Revatio	Sildenafil	Oral tablet and other forms	PDE-5 inhibitor alternative
Uptravi	Selexipag	Oral tablet	Different PAH pathway and titration profile
Tracleer	Bosentan	Oral tablet and dispersible tablet	Older endothelin receptor antagonist

Opsynvi’s primary commercial differentiation is regimen simplification. Its main competitive risk is that physicians may continue prescribing the individual components because of dose flexibility, formulary preference, or the need to adjust one agent independently.

A generic fixed-dose combination would compete against both branded Opsynvi and separate generic or authorized-generic components. That makes manufacturing cost and reimbursement positioning important.

What generic launch scenarios exist for Opsynvi?

Early Paragraph IV launch

A generic company challenges a listed patent and prevails in litigation, obtains a favorable settlement, or launches at risk. This scenario creates the highest immediate erosion risk but also carries the greatest litigation exposure.

Post-expiry launch

The applicant accepts patent expiry and enters after the relevant listed patents expire. Market entry would likely be more predictable but could face competition from multiple ANDA applicants.

Authorized-generic competition

The brand holder may commercialize or license an authorized generic. This can reduce the price gap and preserve part of the brand franchise while limiting independent generic economics.

Component substitution

Physicians may prescribe separate macitentan and tadalafil products instead of the fixed-dose combination. This is a commercial constraint on both the brand and generic combination because the market has therapeutic substitutes even before an exact generic is available.

What is the FDA regulatory status and commercial outlook for Opsynvi?

The FDA approved Opsynvi in March 2024 for adults with PAH.[1] The approval was supported by the A DUE clinical program, which evaluated the fixed-dose combination in patients receiving stable background therapy or transitioning from the individual components.[4]

Johnson & Johnson reports PAH products within its Innovative Medicine portfolio, but publicly reported company filings do not necessarily disclose separate Opsynvi revenue. Product-level revenue exposure should therefore be modeled from prescription volume, net price, patient persistence, payer access, and conversion from separate macitentan and tadalafil therapy rather than from a separately reported revenue line.

The addressable market is limited to a specialty PAH population, but annual treatment costs for branded PAH products are high. Commercial performance will depend on:

• Conversion of patients already taking both components.
• Use in newly diagnosed or treatment-escalation patients.
• Payer acceptance of the fixed-dose combination.
• Ability to preserve branded pricing against future generic components.
• Patent durability.
• Physician preference for independent dose titration.

Key Takeaways

• Opsynvi is a macitentan/tadalafil fixed-dose tablet approved by the FDA in March 2024.
• The principal formulation challenge is combining a low-dose, potent endothelin receptor antagonist with a higher-dose, poorly soluble PDE-5 inhibitor.
• Conventional excipients can support a generic, but particle engineering, granulation control, dissolution enhancement, and blend uniformity are likely to determine development success.
• The strongest formulation IP would likely claim defined composition, dissolution, solid-state, stability, or manufacturing attributes rather than a broad combination alone.
• Opsynvi has no biosimilar pathway. Generic competition will use the ANDA process, including Paragraph IV challenges and possible Hatch-Waxman litigation.
• Commercial opportunities include generic formulation platforms, co-processed excipients, solubility-enhancing systems, specialty-market supply, and improved fixed-dose or patient-friendly presentations.
• The product’s commercial value depends on adherence and conversion from separately prescribed macitentan and tadalafil, while its principal market risks are component substitution, payer restrictions, and future generic entry.

FAQs About Opsynvi Excipient Strategy and Market Opportunities

Can a generic Opsynvi use different excipients from the branded product?

Yes. A generic applicant generally may use different inactive ingredients if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, labeling, and safety requirements. The applicant must also address any excipient-related patent claims.

Is tadalafil the main dissolution challenge in Opsynvi?

Tadalafil is likely to be a major dissolution and tablet-load challenge because it is present at 20 mg or 40 mg and has limited aqueous solubility. Macitentan also requires control of wetting, content uniformity, and solid-state behavior.

Does Opsynvi have biosimilar competition?

No. Opsynvi contains small-molecule active ingredients. Competing products would be developed as generic drugs through the ANDA pathway, not as biosimilars under the Public Health Service Act.

What excipient technology has the greatest commercial potential for Opsynvi generics?

High-functionality direct-compression excipients, co-processed disintegrants, wetting systems, and solubility-enhancing polymers have the strongest near-term potential. Their value depends on improving dissolution and content uniformity without increasing tablet size or process complexity.

Could an orally disintegrating Opsynvi product be commercially attractive?

Possibly, but it would require proof of patient benefit, acceptable taste and mouthfeel, adequate dose loading, and a viable regulatory pathway. The high tadalafil dose may make an orally disintegrating format technically difficult and commercially less attractive than a smaller conventional tablet.

References

1. U.S. Food and Drug Administration. (2024). FDA approves first-in-class treatment for pulmonary arterial hypertension, Opsynvi.
2. Janssen Pharmaceuticals, Inc. (2024). Opsynvi (macitentan and tadalafil) tablets: U.S. prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. Pulido, T., et al. (2024). Fixed-dose macitentan and tadalafil combination therapy in pulmonary arterial hypertension. Clinical trial and regulatory materials supporting the A DUE program.